CTOs on the Move

Whitmyer Biomechanix

www.whitbio.com

 
Whitmyer Biomechanix is a Tallahassee, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.whitbio.com
  • 3373 Garber Dr
    Tallahassee, FL USA 32303
  • Phone: 850.656.9448

Executives

Name Title Contact Details

Similar Companies

FirstString Research Inc

FirstString Research was founded on a vision to deliver clinically relevant and effective solutions for the treatment of diseases based upon insights and understanding from the molecular and cellular contexts that define the underlying pathology.

Elastrin Therapeutics

Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice.

NantKwest

NantKwest is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.

Affinia Therapeutics

We are working to methodically engineer durable gene therapies for people with devastating diseases.

Botanix Pharmaceuticals

Botanix Pharmaceuticals is a biotechnology company listed on the ASX (ASX: BOT) with headquarters in Perth, Australia, and Philadelphia, USA. The company specializes in clinical-stage dermatology and antimicrobial treatments, focusing on synthetic cannabinoid-based therapies that utilize cannabidiol (CBD) and its proprietary skin-delivery technology, Permetrex™. The companys product pipeline includes several innovative therapies aimed at addressing common dermatological conditions. These include BTX 1503 for moderate-to-severe acne, BTX 1702 for rosacea, and BTX 1204A for moderate atopic dermatitis. Additionally, BTX 1801 targets infections in hemodialysis patients and other antimicrobial applications. All products leverage the Permetrex™ delivery system to enhance skin absorption, and Botanix is also exploring veterinary applications for atopic dermatitis. Botanix aims to improve patient outcomes by addressing unmet needs in dermatology and antimicrobial resistance, positioning itself as a leader in cannabinoid-based dermatological treatments.